AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca cash
Cash and short-term investments held at the end of each period.
AstraZeneca's cash was $4.89B at Jun 30, 2026. For fiscal 2025 it was $5.71B, up 4.1% from the year before. Over ten years it grew -0.9% a year on average. The highest annual figure on record is $7.83B in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.71B | +4.1% |
| FY2024 | Dec 31, 2024 | $5.49B | -6.0% |
| FY2023 | Dec 31, 2023 | $5.84B | -5.3% |
| FY2022 | Dec 31, 2022 | $6.17B | -2.6% |
| FY2021 | Dec 31, 2021 | $6.33B | -19.2% |
| FY2020 | Dec 31, 2020 | $7.83B | +45.9% |
| FY2019 | Dec 31, 2019 | $5.37B | +11.1% |
| FY2018 | Dec 31, 2018 | $4.83B | +45.3% |
| FY2017 | Dec 31, 2017 | $3.32B | -33.8% |
| FY2016 | Dec 31, 2016 | $5.02B | -19.6% |
| FY2015 | Dec 31, 2015 | $6.24B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.89B | -29.3% |
| Q4 FY2025 | Dec 31, 2025 | $5.71B | -2.2% |
| Q2 FY2025 | Jun 30, 2025 | $7.06B | +24.6% |
| Q4 FY2024 | Dec 31, 2024 | $5.49B | -11.0% |
| Q2 FY2024 | Jun 30, 2024 | $6.92B | +43.6% |
| Q4 FY2023 | Dec 31, 2023 | $5.84B | -7.7% |
| Q2 FY2023 | Jun 30, 2023 | $5.66B | -63.6% |
| Q4 FY2022 | Dec 31, 2022 | $6.17B | -21.3% |
| Q2 FY2022 | Jun 30, 2022 | $4.82B | -15.1% |
| Q4 FY2021 | Dec 31, 2021 | $6.33B | +17.9% |
| Q2 FY2021 | Jun 30, 2021 | $15.57B | +186.8% |
| Q4 FY2020 | Dec 31, 2020 | $7.83B | +62.1% |
| Q2 FY2020 | Jun 30, 2020 | $5.67B | +90.5% |
| Q4 FY2019 | Dec 31, 2019 | $5.37B | +61.5% |
| Q2 FY2019 | Jun 30, 2019 | $5.43B | +3.6% |
| Q4 FY2018 | Dec 31, 2018 | $4.83B | -3.7% |
| Q2 FY2018 | Jun 30, 2018 | $2.98B | -52.3% |
| Q4 FY2017 | Dec 31, 2017 | $3.32B | – |
| Q2 FY2017 | Jun 30, 2017 | $5.24B | – |
| Q4 FY2016 | Dec 31, 2016 | $5.02B | – |
| Q4 FY2015 | Dec 31, 2015 | $6.24B | – |
See a number that looks wrong?